At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 756 enrolled
Drug / intervention
Placebo +3 moredrug
Likely dose
Aliskiren 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Eight-week Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal
In Brief
A Phase 3 clinical trial evaluating Placebo, Aliskiren 75 mg, and 2 other interventions for Hypertension. Completed, enrolled 756 participants across 8 sites in 8 countries.
Detailed Summary
This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when given with a light meal.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesArgentina, Czechia, Germany, Iceland, Italy, Netherlands, Poland, Slovakia
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedJun 2008
Primary CompletionApr 2009
TodayJul 2026
First PostedJun 27, 2008
Enrollment StartMay 1, 2008
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.0 years ago
Interventions
Placebodrug
Placebo tablet taken once daily in the morning with a light meal.
Aliskiren 75 mgdrug
Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
Aliskiren 150 mgdrug
Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
Aliskiren 300 mgdrug
Aliskiren 300 mg tablet taken once daily in the morning with a light meal.